--- title: "Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 56%" type: "News" locale: "en" url: "https://longbridge.com/en/news/276081251.md" description: "Biosino Bio-Technology and Science Incorporation (HKG:8247) shares have surged 56% in the past month, contributing to an impressive 803% gain over the last year. Despite this, the company's low price-to-sales (P/S) ratio of 3.2x raises concerns due to declining revenue, which fell 21% last year and 35% over three years. The biotech industry is expected to grow by 650% next year, highlighting Biosino's struggles. Investors remain cautious, as the low P/S reflects skepticism about future revenue growth, potentially limiting share price increases unless performance improves." datetime: "2026-02-16T22:46:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276081251.md) - [en](https://longbridge.com/en/news/276081251.md) - [zh-HK](https://longbridge.com/zh-HK/news/276081251.md) --- # Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 56% **Biosino Bio-Technology and Science Incorporation** (HKG:8247) shares have continued their recent momentum with a 56% gain in the last month alone. The last 30 days were the cherry on top of the stock's 803% gain in the last year, which is nothing short of spectacular. Even after such a large jump in price, Biosino Bio-Technology and Science Incorporation may still look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 3.2x, considering almost half of all companies in the Biotechs industry in Hong Kong have P/S ratios greater than 14.2x and even P/S higher than 71x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. View our latest analysis for Biosino Bio-Technology and Science Incorporation SEHK:8247 Price to Sales Ratio vs Industry February 16th 2026 ### What Does Biosino Bio-Technology and Science Incorporation's Recent Performance Look Like? For instance, Biosino Bio-Technology and Science Incorporation's receding revenue in recent times would have to be some food for thought. Perhaps the market believes the recent revenue performance isn't good enough to keep up the industry, causing the P/S ratio to suffer. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour. Want the full picture on earnings, revenue and cash flow for the company? Then our **free** report on Biosino Bio-Technology and Science Incorporation will help you shine a light on its historical performance. ## What Are Revenue Growth Metrics Telling Us About The Low P/S? In order to justify its P/S ratio, Biosino Bio-Technology and Science Incorporation would need to produce anemic growth that's substantially trailing the industry. Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 21%. This means it has also seen a slide in revenue over the longer-term as revenue is down 35% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time. In contrast to the company, the rest of the industry is expected to grow by 650% over the next year, which really puts the company's recent medium-term revenue decline into perspective. With this information, we are not surprised that Biosino Bio-Technology and Science Incorporation is trading at a P/S lower than the industry. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth. ## The Key Takeaway Shares in Biosino Bio-Technology and Science Incorporation have risen appreciably however, its P/S is still subdued. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company. As we suspected, our examination of Biosino Bio-Technology and Science Incorporation revealed its shrinking revenue over the medium-term is contributing to its low P/S, given the industry is set to grow. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels. Plus, you should also learn about this **1 warning sign we've spotted with Biosino Bio-Technology and Science Incorporation**. If these **risks are making you reconsider your opinion on Biosino Bio-Technology and Science Incorporation**, explore our interactive list of high quality stocks to get an idea of what else is out there. ### Valuation is complex, but we're here to simplify it. Discover if Biosino Bio-Technology and Science Incorporation might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [08247.HK](https://longbridge.com/en/quote/08247.HK.md) ## Related News & Research - [US MBA Mortgage Applications 15-May: -2.3% (prev 1.7%) - 30-Yr Mortgage Rate: 6.56% (prev 6.46%)](https://longbridge.com/en/news/287055363.md) - [14:47 ET6th Annual Midwest Design Awards Entry Period Now Open](https://longbridge.com/en/news/286808240.md) - [11:48 ETInventHelp Inventor Develops New Remote Control Finder (TKA-458)](https://longbridge.com/en/news/286941635.md) - [JPMorgan lowers 2026 gold forecast, still sees rally towards $6,000 on renewed demand](https://longbridge.com/en/news/286715908.md) - [Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances](https://longbridge.com/en/news/286835606.md)